Haemophilia prophylaxis in Sweden

Area of Science:

• Hematology
• Pediatric Medicine
• Pharmacology

Background:

• Severe hemophilia A poses significant risks of bleeding and joint damage in children.
• Current treatments often focus on managing acute bleeding events rather than prevention.
• Preventing arthropathy and severe bleeding is crucial for improving long-term quality of life.

Purpose of the Study:

• To evaluate the efficacy of prophylactic antihaemophilic factor (AHF) concentrate infusions in converting severe hemophilia A to a moderate form.
• To assess the impact of this prophylactic regimen on preventing arthropathy and severe bleeding episodes.
• To determine the optimal dosing and interval for AHF concentrate administration through survival studies.

Main Methods:

• 29 boys aged 4-18 with severe hemophilia A received AHF concentrate prophylaxis for 2-13 years.
• Dosing and intervals were adjusted based on AHF survival studies, aiming for 30-45% AHF levels at 5-12 day intervals.
• Patient outcomes, including bleeding frequency/severity, joint health, and hospitalizations, were monitored.

Main Results:

• Prophylaxis successfully reduced hemophilia A from severe to moderate in most patients.
• Bleeding episodes became less frequent and less severe, enabling a near-normal life for the children.
• Hospital stays were significantly reduced; joint function in previously unaffected patients remained comparable to moderate hemophilia.
• Two patients developed inhibitors (anticoagulants), with no other adverse effects reported.

Conclusions:

• Prophylactic AHF concentrate infusions are effective in mitigating the severity of hemophilia A in children.
• This regimen significantly improves quality of life by reducing bleeding complications and joint damage.
• The Swedish prophylactic regimen demonstrates a successful strategy for managing severe hemophilia A.